About: Girentuximab antibody was in-licensed from Wilex AG, a small German biotech company, who completed the initial Phase 3 study of the imaging agent as a patient selection tool. Telix has now in-licensed this product and is developing 124I-TX250 for the diagnosis of clear cell renal cell carcinoma (ccRCC) and 177Lu-TX250 for the treatment of metastatic ccRCC.
Mechanism of Action: The chimeric antibody cG250 (girentuximab) binds carbonic anhydrase IX; a cell-surface antigen which is highly and homogenously expressed in over 90% of ccRCC patients. It is also expressed in a significant proportion of other cancer types including non-small cell lung carcinoma (NSCLC) and ovarian cancer.
Importance in ccRCC diagnosis: There is a significant unmet need for better diagnostic methods for preoperative characterisation of ccRCC. With current standard of care, renal masses enhanced on CT are malignant until otherwise proven benign by biopsy. Biopsies are invasive and costly and have mixed accuracy data, depending on the centre, size and location of the tumour.